$21.490
+0.449 (+2.09%)收盤時
BDSX 資訊
BDSX 事件
Biodesix Advances Tumor-Informed and Tumor-Naive MRD Solutions
Biodesix (BDSX) announced strategic progress in two collaborative programs for tumor-informed and tumor-naive Molecular Residual Disease - or MRD - solutions intended to support cancer centers and clinical laboratories. Both solutions detect circulating tumor DNA - ctDNA -, the tumor DNA that a cancer sheds into the blood, to assess whether disease remains or is returning after treatment. The tumor-informed solution is the result of a multi-year collaboration with Bio-Rad Laboratories (BIO). The tumor-naive solution is a newly launched program with Thermo Fisher Scientific (TMO) that extends a collaboration for companion diagnostic validation and other development work. Both approaches will be validated by Biodesix in collaboration with key investigators at Memorial Sloan Kettering Cancer Center or MSK, and are designed to run on partner platforms already installed in laboratories around the world. Tumor-informed testing is generally the most sensitive option when tumor tissue is available, and tumor-naive testing extends monitoring to patients whose tissue is unavailable or insufficient. Biodesix is advancing both, drawing on its proprietary Diagnostic Cortex bioinformatics platform. The two programs build on MRD data that Biodesix and its collaborators have presented at scientific meetings over the past two years.
Biodesix Files to Sell 375,000 Shares of Common Stock
Biodesix files to sell 375,000 shares of common stock for holders
Biodesix Expects FY26 Revenue of $108M to $114M
Consensus $108.68M. Backs FY26 gross margin view 80%. Still sees adjusted EBITDA continuing improvement on path to profitability. The company said, "For full year 2026, the Company expects total revenue of $108-114 million, with the midpoint representing approximately 25% growth over 2025. Biodesix expects continued progress toward achieving and maintaining Adjusted EBITDA profitability, driven by increasing sales productivity, expanded clinical evidence supporting the Nodify Lung tests, growth in the Development Services pipeline, and demonstrated operating leverage."
Biodesix Q1 Revenue at $22.29M, Below Consensus
Reports Q1 revenue $22.29M, consensus $23.18M. "Biodesix delivered exceptional first quarter results that reflect strong momentum across both our Diagnostic Testing and our Development Services business," said Scott Hutton, Chief Executive Officer. "Test volumes grew 29%, Development Services revenue doubled, and average revenue per test increased through expanded payer coverage and improved revenue cycle management, driving total revenue growth of 42% year over year. We were also recognized as a Top Workplace for the third consecutive year, reinforcing that our culture is not aspirational, its operational. Our first quarter results reflect a disciplined culture of execution in service to our partners, healthcare providers, and the patients they serve. With strong performance across both business lines and continued operational leverage, we are raising our full-year 2026 guidance and remain on a clear path toward profitability."
Company Sees FY26 Gross Margin at 80%
Sees FY26 gross margin 80%. The company said, "The Company anticipates generating between $106-112 million in total revenue in 2026, the mid-point representing 23% growth over 2025 total revenue, and expects continued improvement toward sustained Adjusted EBITDA positivity. The revenue growth and improvement on the path to profitability is expected to be driven by the increasing productivity across our expanded sales organization, improvements to average revenue per test demonstrated in the second half of 2025, additional clinical data on the Nodify Lung tests to help drive adoption from healthcare providers and payers, increases in Development Services pipeline, and the demonstrated operating leverage."
相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。